Loading…
← CockpitCompetitor Analysis › 4592.T SanBio Co., Ltd.Open in the cockpit ↗

SanBio Co., Ltd.4592.TCompetitor analysis, valuation and peers

Japan · JPY·Health Care›Pharmaceuticals: Major
Momentum laggard 5
Mkt cap
$386M
US dollars, full cap
Free float
75%
of shares outstanding
$/day
$4.58M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 5.0%
Hurdle
n/a
no reverse DCF
Next earnings
27 days
15 Dec 2026
Close · JPY¥808
1D0.0%
1W-6.3%
1M-12.7%
3M-22.5%
6M-55.4%
YTD-52.2%
1Y-71.6%
ATR %5.7%
52w lowhigh71.4% off high

What SanBio does

Employees: 33

SanBio at a glance

Size SanBio (4592.T) is a Japan Health Care company (Pharmaceuticals: Major) with a market value of $386M, the 1197th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥808 on 18 Nov 2026.

Performance Over six months the shares fell 55.4%, against -20.3% for the median peer and -1.4% for the Japan market (cap-weighted) — 3rd lowest of 19 in its peer set.

Next results Next results expected around 15 Dec 2026 (exchange calendar; dates can move).

Relative performance

608010021 May 202621 Aug 202618 Nov 2026Peer median 814592.T 48
Six months, rebased to 100: SanBio against the median of its 20 peers (local-currency closes).

SanBio financials

Reported figures in JPY; fiscal year ends 2026-01-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue¥0¥0¥0¥0¥0
Revenue growth—————
Gross profit-¥31.5M-¥8.05M-¥9.37M-¥14.5M-¥24.6M
EBITDA-¥3.79B-¥3.79B-¥3.51B-¥4.53B-¥7.87B
Net income-¥3.64B-¥3.84B-¥2.88B-¥2.64B-¥5.56B
Free cash flown/a-¥3.84B-¥3.62B-¥4.79B-¥7.46B
Capital expendituren/a¥32.8M¥4.89M¥55.0M¥8.00M
Total debt¥1.13B¥1.24B¥397M¥665M¥933M

Quarterly statements and history in the cockpit →

SanBio competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-40%-20%0%30053400286842CAVTX300452219A4552IRD688399300636PBYISPRY002872MPLT30111100258165354592.T6-month return →1-month return →
Up and to the right = strong over both horizons. SanBio is the large dot.

SanBio competitors and peer comparison

How SanBio compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

SanBio against its 20 peers (data as of 18 Nov 2026)
Measure4592.TPeer medianRank in peer set
1-month return-12.7%-13.1%10th highest of 20
6-month return-55.4%-20.3%3rd lowest of 19
Distance from 52-week high-71.4%-39.2%4th lowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
SanBio 4592.TJapan$386M-55%n/an/an/an/an/a
Gansu Longshenrongfa Pharmaceutical Industry 300534.SZChina$386M-2%-21%8%3.7×20.9%+28.2%
Shukra Pharmaceuticals SHUKRAPHAR.NSIndia$387Mn/a+222%54%32.0×n/an/a
Lifecome Biochemistry 002868.SZChina$384M-54%-23%-3%6.2×n/an/a
iX Biopharma 42C.SISingapore$387M+28%-12%-140%71.6×n/an/a
Avalo Therapeutics AVTXUnited States$387M-59%-69%-161,961%n/an/an/a
Anhui Sunhere Pharmaceutical Excipients 300452.SZChina$388M-17%+9%19%2.2×-5.5%+12.2%
Heartseed 219A.TJapan$392M+53%+197%9%21.9×46.5%+73.2%
JCR Pharmaceuticals 4552.TJapan$379M-5%+3%-14%2.9×n/an/a
Opus Genetics IRDUnited States$379M-22%-46%-778%41.2×n/an/a
Jiangsu Bioperfectus Technologies 688399.SSChina$374M-51%-8%-23%4.4×n/an/a
Jiangxi Synergy Pharmaceutical 300636.SZChina$398M-13%-3%2%3.4×14.9%+13.7%
Puma Biotechnology PBYIUnited States$373M+3%+9%11%1.2×0.1%+0.3%
ARS Pharmaceuticals SPRYUnited States$371M-53%-14%-162%2.9×n/an/a
Tiansheng Pharmaceutical 002872.SZChina$371M-1%-1%-13%4.9×22.2%-15.7%
MapLight Therapeutics MPLTUnited States$370M-76%n/an/an/an/an/a
6467 6467.TWTaiwan$368Mn/an/a-2,618%1,407.9×n/an/a
Guangdong Lifestrong Pharmacy 301111.SZChina$368M-33%+7%-2%7.2×n/an/a
Shandong Sinobioway Biomedicine 002581.SZChina$405M-24%+91%-65%7.9×n/an/a
Beijing Centergate Technologies (Holding) 000931.SZChina$406M-18%-16%2%1.9×9.2%+6.7%
Lumosa Therapeutics 6535.TWOTaiwan$406M-37%-25%-803%399.1×n/an/a

Questions

Which companies are SanBio's closest peers?
The cockpit's peer set: Gansu Longshenrongfa Pharmaceutical Industry (300534.SZ), Shukra Pharmaceuticals (SHUKRAPHAR.NS), Lifecome Biochemistry (002868.SZ), iX Biopharma (42C.SI), Avalo Therapeutics (AVTX), Anhui Sunhere Pharmaceutical Excipients (300452.SZ), Heartseed (219A.T), JCR Pharmaceuticals (4552.T).
How has SanBio stock performed?
Over six months to 18 Nov 2026 the shares returned -55.4% against -20.3% for the median peer; over one year -71.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.